DEALS: GSK, Sirna sign $700M development deal

DEALS

WHO

WITH

WHAT

SCOOP

GSK

Sirna Therapeutics

Development deal

Sirna Therapeutics will develop RNAi therapies for respiratory diseases in a deal worth up to $700 million.

GSK

Pharmacopeia

Research agreement

GSK will pay Pharmacopeia $15 million and the companies will collaborate to deliver therapeutic candidates for development.

Abbott

Myriad Genetics

Research agreement

Abbott and Myriad Genetics have entered into a five-year research agreement to identify new therapeutic targets

Ono Pharmaceutical

Medarex

Development deal

The companies will develop a fully human anti-SDF-1 antibody.

EPIX

Predix

Merger

EPIX will pay $90 million for Predix and gain several advanced clinical programs.

Adventrx Pharmaceuticals

SD Pharmaceuticals

Buyout

Adventrx Pharmaceuticals will buy SD Pharmaceuticals for 2.1 million Adventrx shares. Adventrx will gain rights to eight oncology and infectious disease products.

Daiichi Sankyo

Astellas

Purchase

Daiichi Sankyo has purchased the OTC unit of Astellas for 20 billion yen.

Biogen Idec

Astellas Pharma

Sale

Biogen Idec sold its underperforming psoriasis drug Amevive for $60 million to Astella as part of Biogen's restructuring plan, announced last fall as it grappled with Tysabri problems.

GSK

Kissei

Licensing deal

GSK will pay up to $98 million for Kissei's experimental diabetes drug, which is still in the preclinical stage.

Santen Pharmaceutical

Oakwood

Licensing deal

Santen has licensed the microsphere formulation of a steroid (DE-102) for diabetic macular edema from Oakwood.

AlphaRx

Proprius Pharmaceuticals

Licensing deal

The companies have entered into a license agreement giving Proprius exclusive global rights to AlphaRx's topical NSAID, Indaflex, currently in Phase II trials for osteoarthritis.